HOW HEAT MAKES CHEMOTHERAPY WORK BETTER
DRUG-HEAT INTERACTIONS

Chemosensitisation is the use of a secondary agent — heat, drug, or biological treatment — to make cancer cells more vulnerable to chemotherapy. Hyperthermia is the most extensively used physical chemosensitiser, with decades of clinical evidence supporting its role in HIPEC, HIVEC, and regional chemotherapy protocols.

“Heat does not change the chemotherapy drug — it changes the tumor, making the same drug dose dramatically more lethal to cancer cells.”

• Thermal Chemo Enhancement Ratio (TCER)

  The measure of chemosensitisation. A TCER of 3 means chemotherapy combined with hyperthermia kills three times more cancer cells than the same dose given at normal body temperature. Cisplatin reaches TCER values of 2–4 at 41–43°C — among the highest of any chemotherapy drug.

• Drug-Specific, Not Universal

  Not every chemotherapy drug works better with heat. Cisplatin, mitomycin C, oxaliplatin, and doxorubicin show strong synergy. Taxanes, vinca alkaloids, and methotrexate show little to no enhancement. Choosing the right drug is essential to capturing the chemosensitisation effect.

Chemotherapy is powerful but limited by biological barriers within tumors. Hyperthermia directly attacks each of these limitations.

• Drug Resistance Mechanisms

  Cancer cells deploy drug efflux pumps (P-glycoprotein, MRP1) that expel chemotherapy drugs before they reach lethal concentrations inside the cell. They also activate detoxification pathways like glutathione conjugation that neutralize platinum-based drugs.

• Poor Drug Penetration into Tumors

  Tumors have chaotic, leaky blood vessels and high interstitial pressure that prevent uniform drug distribution. Cells in the center of a tumor — often the most aggressive — receive only a fraction of the drug concentration their neighbors near blood vessels do.

• DNA Repair Capacity

  Many chemotherapy drugs work by damaging cancer cell DNA. But cancer cells can rapidly repair these breaks using homologous recombination and nucleotide excision repair — undoing the chemotherapy's damage before cell death occurs.

• Dose-Limiting Systemic Toxicity

  Higher chemotherapy doses kill more cancer cells — but also cause more severe nausea, bone marrow suppression, neuropathy, and organ toxicity. This ceiling on systemic dose often means cancer cells receive sub-lethal exposure, allowing resistance to develop.

Hyperthermia at 40–43°C attacks every chemotherapy resistance mechanism described above. Here is what happens at the cellular level in the minutes after heat is applied alongside a chemotherapy drug.

• Increases Cell Membrane Permeability

  Heat fluidizes cancer cell membranes, allowing chemotherapy drugs — especially platinum compounds and alkylating agents — to enter cells far more readily. Intracellular drug concentrations can rise by 2–3× without changing the dose given.

• Improves Tumor Blood Flow and Drug Delivery

  Mild hyperthermia dilates tumor blood vessels, temporarily improving perfusion to poorly-supplied zones. This drives more drug into the tumor interior, reaching cells that were previously beyond the reach of effective chemotherapy concentrations.

• Blocks DNA Repair After Drug-Induced Damage

  Heat denatures repair proteins like BRCA2 and Ku70/80 that cancer cells use to mend chemotherapy-induced DNA damage. With repair pathways disabled, breaks caused by cisplatin, mitomycin C, and doxorubicin become permanently lethal.

• Disables Drug Efflux Pumps

  P-glycoprotein and other efflux pumps require ATP and stable membrane structure to function. Heat disrupts both — leaving drugs trapped inside cancer cells where they can do their work, rather than being pumped back out.

• Adds Direct Heat Cytotoxicity

  Above 42°C, heat alone causes cancer cell death through protein denaturation and apoptosis. When combined with chemotherapy, the two damage mechanisms compound — cells that survive one cannot survive both.

Selecting the right drug is critical to capturing the chemosensitisation effect. Below is a clinical reference of which agents synergize meaningfully with hyperthermia and which do not.

Landmark trials demonstrating the chemosensitisation effect across the most common heat-chemotherapy combinations.

Maximum chemosensitisation requires that the drug be present inside cancer cells during the heat window. Sequence and timing determine whether the synergy is captured.

1. 1

   Administer the Chemotherapy Drug

   Drug delivery is timed so that peak intratumoral concentration coincides with the start of heating. For HIPEC and HIVEC, the heated drug solution is delivered directly into the cavity — solving the timing problem by design.

2. 2

   Apply Hyperthermia at 40–43°C

   Tumor tissue is heated to the therapeutic range and maintained for 60–90 minutes. Real-time temperature monitoring ensures uniform heat distribution without hotspots.

3. 3

   Maintain Drug-Heat Overlap

   The drug must be biologically active inside cancer cells throughout the heating window. Pre-heating cools the tumor before drug arrives; post-heating arrives too late after drug clearance. Same-session, same-window delivery is non-negotiable.

4. 4

   Monitor for Synergistic Toxicity

   While heat-enhanced cytotoxicity targets the tumor, some normal tissues may also receive amplified drug effect. Monitoring focuses on bone marrow, kidney function, and skin integrity at the heated site.

5. 5

   Repeat Per Protocol

   HIPEC and HIVEC are typically single-session interventions tied to surgery. Regional hyperthermia for sarcoma or pelvic tumors is paired with 4–8 chemotherapy cycles, scheduled once or twice per week.

Explore the full hyperthermia knowledge base and adjacent treatment modalities.

Frequently Asked Questions

Common questions about combining hyperthermia with chemotherapy in cancer treatment.